Methods and compositions for the treatment of steatosis-associated disorders
AssigneesDuke University, National University of Singapore
InventorsDwight D. Koeberl, Paul M. Yen, Benjamin L. Farah
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
Claims19
A method of treating a steatosis-associated disorder in a subject, the method comprising:
- administering to the subject in need thereof an autophagy-inducing agent, wherein the autophagy-inducing agent is a PPAR-α agonist, and wherein the steatosis-associated disorder is Glycogen Storage Disease Type I (GSD I).
A method of reversing steatosis in a subject in need thereof, the method comprising administering to the subject an autophagy-inducing agent, wherein the autophagy-inducing agent is a PPAR-α agonist, wherein the subject has a steatosis-associated disorder, and wherein the steatosis-associated disorder is GSD I.
A method of modulating autophagy in a subject with a steatosis-associated disorder, the method comprising administering to the subject an autophagy-inducing agent, wherein the autophagy-inducing agent is a PPAR-α agonist, and wherein the steatosis-associated disorder is GSD I.
Dependencies are inferred from the claim text.